Has Houman Vaghefi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,610 in general payments to Houman Vaghefi, MD across 57 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Houman Vaghefi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Houman Vaghefi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Houman Vaghefi, MD

Radiation Oncology · Goshen, INNPI 1174713127

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (47.8%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Varian Medical Systems, Inc. at 54.4% of the total. Reporting peaked in 2019 at $2,878 and has fallen 82.1% since, to $516 in 2025. Among radiation oncology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,610in general payments, 2019–2025

Across 57 payments — averaging $80.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Varian Medical Systems, Inc.$3K
Tempus AI, Inc$496
E.r. Squibb & Sons, L.L.C.$414
Radformation Inc$350
Accuray Incorporated$202
Sanofi$125
plus $515 from 16 others

$4,000in research payments, 2019–2025

Across 1 payment — averaging $4000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novocure GmbH$4K

What the payments were for

Speaking & faculty fees$3508%
Travel & lodging$2,05845%
Food & beverage$2,20248%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Varian Medical Systems, Inc.	14	$2,508
Tempus AI, Inc	15	$496
E.r. Squibb & Sons, L.L.C.	2	$414
Radformation Inc	1	$350
Accuray Incorporated	1	$202
Sanofi	1	$125
Novocure Inc.	1	$70
Bayer	3	$50
Boston Scientific	2	$50
Novartis	2	$42
Myriad Genetic Laboratories, Inc.	2	$41
Siemens Medical Solutions USA, Inc.	1	$33
Merck	2	$32
Elekta, Inc.	2	$30
Pharmacosmos Therapeutics Inc.	1	$28
Genmab U.S., Inc.	1	$26
Takeda Pharmaceuticals U.S.A., Inc.	1	$24
Kyowa Kirin, Inc.	1	$20
Progenics Pharmaceuticals, Inc.	1	$19
AbbVie	1	$18
Bioprotect Medical, Inc.	1	$16
Tactile Systems Technology Inc	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,610 in reported general payments places this provider in the 90th percentile of 116 radiation oncology providers in Indiana.

See all radiation oncology providers in Indiana →

Medicare billing

Part B allowed, 2024

$194,355

Medicare patients

188

Services billed

2,015

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tamsulosin Hcl	45	$389

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Goshen

James WheelerGoshen$2K
Irina SparksGoshen$2K
Brian ChangFort Wayne$13K
Michael EatonIndianapolis$11K
William PorterMadison$8K
Binh TranMishawaka$7K
Gordon WatsonIndianapolis$6K
John CoxIndianapolis$5K
Peter GarrettIndianapolis$5K
Garrett JensenIndianapolis$4K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →